




Human Type IV Collagen

Cat. No.	Format	Size
1250-01S	Purified Protein - Solution	0.5 mg



ELISA plate was coated with serially diluted Human Type IV Collagen-Solution (SB Cat. No. 1250-01S). Purified collagen was detected with Goat Anti-Type I Collagen-BIOT (SB Cat. No. 1310-08), Goat Anti-Type II Collagen-BIOT (SB Cat. No. 1320-08), Goat Anti-Type III Collagen-BIOT (SB Cat. No. 1330-08), Goat Anti-Type IV Collagen-BIOT (SB Cat. No. 1340-08), Goat Anti-Type V Collagen-BIOT (SB Cat. No. 1350-08), and Goat Anti-Type VI Collagen-BIOT (SB Cat. No. 1360-08) followed by Streptavidin-HRP (SB Cat. No. 7100-05).

Overview

Source	Placental villi
Purification	Controlled and limited pepsin digestion followed by selective salt precipitation
Purity	> 90% by SDS-PAGE
Alternate Name(s)	COL4A1, COL4A2, COL4A3, COL4A4, COL4A5, COL4A6

Description

Collagen is the main structural protein in the extracellular space and is the most abundant protein in the ECM. Collagens are divided into two classes - fibril (types I, II, III, V) and non-fibril (types IV, VI). Type IV collagen is primarily expressed in the basal lamina and therefore constitutes a portion of the basement membrane. Type IV collagen mutations are associated with Alport syndrome and the $\alpha 3(IV)$ chain is thought to be the antigen implicated in Goodpasture's syndrome. Type IV collagen is comprised of six isomeric chains designated $\alpha 1(IV)$ to $\alpha 6(IV)$.

Applications

- ELISA – Quality tested ^{2,4}
- SDS-PAGE – Quality tested ¹
- Coating Material for –
 - Adhesion Studies – Reported in literature ^{5,6}
 - Blood Disorder Studies – Reported in literature ^{2,4}
 - Differentiation Studies – Reported in literature ⁷
 - ECM Interaction Studies – Reported in literature ^{8,9}

Handling and Storage

- The purified protein is supplied as a solution of 0.5 mg collagen in 1.0 mL of 500 mM acetic acid. Store at 2-8°C.
- Reagent is stable for the period shown on the label if stored as directed.

Warning

Reagent contains acetic acid. Please refer to product specific SDS.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

References

1. Kim T, Moon JH, Savard CE, Kuver R, Lee SP. Effects of lipopolysaccharide on platelet-derived growth factor isoform and receptor expression in cultured rat common bile duct fibroblasts and cholangiocytes. *J Gastroenterol Hepatol.* 2009;24:1218-25. (SDS-PAGE)
2. Doruelo AL, Haberichter SL, Christopherson PA, Boggio LN, Gupta S, Lentz SR, et al. Clinical and laboratory phenotype variability in type 2M von Willebrand disease. *J Thromb Haemost.* 2017;15:1559-66. (ELISA, Coating, Blood Disorder Studies)
3. Garcia J, Flood VH, Haberichter SL, Fahs SA, Mattson JG, Geurts AM, et al. A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9. *Res Pract Thromb Haemost.* 2019;4:64-71. (ELISA, Coating, Blood Disorder Studies)
4. Chen W, Voos KM, Josephson CD, Li R. Short-acting anti-VWF (von Willebrand factor) aptamer improves the recovery, survival, and hemostatic functions of refrigerated platelets. *Arterioscler Thromb Vasc Biol.* 2019;39:2028-37. (ELISA, Coating, Blood Disorder Studies)
5. Midwood KS, Salter DM. NG2/HMPG modulation of human articular chondrocyte adhesion to type VI collagen is lost in osteoarthritis. *J Pathol.* 2001;195:631-5. (Coating, Adhesion Studies)
6. Imakawa K, Imai M, Sakai A, Suzuki M, Nagaoka K, Sakai S, et al. Regulation of conceptus adhesion by endometrial CXC chemokines during the implantation period in sheep. *Mol Reprod Dev.* 2006;73:850-8. (Coating, Adhesion Studies)
7. Hohn H, Denker H. The role of cell shape for differentiation of choriocarcinoma cells on extracellular matrix. *Exp Cell Res.* 1994;215:40-50. (Coating, Differentiation Studies)
8. Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, Hook M. Binding of the proteoglycan decorin to collagen type VI. *J Biol Chem.* 1992;267:5250-6. (Coating, ECM Interaction Studies)
9. Liu Z, Han X, Chen R, Zhang K, Li Y, Fruge S, et al. Microfluidic mapping of cancer cell-protein binding interaction. *ACS Appl Mater Interfaces.* 2017;9:22143-8. (Coating, ECM Interaction Studies)

In accordance with current Good Manufacturing and Good Laboratory Practices (cGMP/cGLP), any protein of human blood origin should be handled pursuant to your organization's documented safety procedures and as if it is capable of transmitting infection. This product has **NOT** been tested for viral, bacterial, or other infectious agents such as, but not limited to, HIV, HbsAg, and HCV.

TB1250-01
12-Feb-20

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA **Mailing Address:** P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • **Fax:** 205.945.8768

Email: info@southernbiotech.com • **Website:** www.southernbiotech.com